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Abstract 
Background: Urinary tract infection (UTI) is a major complication in patients who receive the kidney trans-
plant. We aimed to evaluate the prevalence and antimicrobial resistance of bacterial uropathogens isolated 
from Iranian kidney transplant recipients.  
Methods: We searched according to Prisma protocol for UTI infection, prevalence, occurrence and distribu-
tion of bacteria and their pattern of antibiotic resistance among Iranian patients who receive kidney transplant 
through online electronic databases with MeSh terms and text words in published references in both Persian 
and English languages during 1990-2017. Data analysis was performed using Comprehensive meta-analysis 
software (CMA) by Cochrane Q and I2 Random Effects Model. 
Results: Eleven studies met the eligible inclusion criteria. The prevalence of UTI among kidney transplant 
patients varied from 11.7% to 67.5%. The combined prevalence of UTI was 32.6%. Among Gram-negative 
pathogens causing UTI, E. coli was the most dominant followed by Klebsiella pneumonia with prevalence 41.3% 
and 11.9%, respectively. Also, amongst Gram-positive bacteria, the highest prevalence belonged to Enterococcus 
spp. (9.8%) and coagulase-negative Staphylococci (9.4%). Also in Gram-negative pathogens, the most re-
sistance was to ampicillin (91.2%), followed by ceftazidime (89.5%).  The minimum resistance was against 
imipenem with prevalence 14.3%. 
Conclusion: The combined prevalence of UTI was 32.6%. Gram-negative pathogens especially E. coli were 
the most agents of UTI in Iranian patients who receive kidney transplant. Also, in gram-negative pathogens, 
the most resistance was to ampicillin that it needs a new strategy for prophylaxis and treatment of UTI after 
the kidney transplant.  
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Introduction 
 
Organ transplant has been identified as a major 
and selective treatment for patients with a disabil-
ity and has increased in recent years, and so far, 
about 11,712 patients are waiting for an organ 
transplant. The advantages of the organ trans-
plant are; safety in immune-compromised people 
and cost consuming (1). Due to increased longev-
ity and improved living conditions in receiving 
transplants, organ donation is rising in the United 
States and kidney transplant is the most common 
type. In Iran, the donation of organs of live peo-
ple and patients with brain death has steadily in-
creased, so that in 2013, the largest number of 
kidney and liver donations reported in the Middle 
East (2, 3). One of the organs with the ability to 
transplantation can mention to the kidney, bone 
marrow, liver, heart, lung, eye, and in some cases, 
pancreas and intestines. Immune suppression is 
the most important factor in the prone of indi-
viduals receiving a transplant to infections. Cardi-
ac complications, thrombosis, blood infections, 
pyelonephritis, hospital infections, intravenous 
and genital catheter infections are some of the 
problems encountered by transplants.  
Transplant individuals are affected by a variety of 
viral, protozoal, fungal and bacterial infections (4, 
5). Bacterial infections are more common and 
have a broader form so that they are known to be 
the most important causes of infection in these 
patients (6). Bacterial infection was created in the 
early days after transplantation and according to 
the reports, 82% of fever after liver transplants, 
22-30% of heart transplantation infections, 47% 
of kidney transplantation infections, 35% of 
transplantation pancreas infections, and 54% of 
lung transplantation infections are caused by dif-
ferent bacterial agents (7). Multidrug resistant 
(MDR) bacteria causing infections in transplant 
patients, and it has become a fundamental prob-
lem in the treatment of infected patients with 
methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococci (VRE), Enterobac-
teriaceae resistant to ciprofloxacin, carbapenem 
and fluoroquinolones, polymyxin B and ciprof-
loxacin resistant Pseudomonas aeruginosa, car-
bapenem-resistant Acinetobacter baumannii, 
imipenem and ciprofloxacin resistant Burkhold-
eria (8, 9). 
The most common of these transplants is the kidney 
transplant which its recipients are more prone to in-
fections especially urinary tract infection (UTI). The 
predisposing factors are; diabetes, immune deficiency 
and underlying diseases (10). UTI accounts for 60% 
of transplant infections and has the highest mortality 
rate. This type of infection occurs during the first 6 
months after renal transplantation and based on clini-
cal symptoms; in the first month, asymptomatic bac-
teriuria in 22-71%, asymptomatic infection in 12-12%, 
and acute pyelonephritis occur in 6.6% of patients.  
The likelihood of the occurrence of pyelonephritis in 
kidney recipients is high within the first six months 
post-transplant period and is also associated with the 
risk of transplant failure and death. Accordingly, it is 
also associated with the risk of kidney failure and 
death. For these reasons, acute bacteremia and acute 
cystitis do not affect individual survival and function 
of the urinary tract, but acute pyelonephritis can be 
dangerous in a short time (11).  
Despite the advanced surgical techniques, antimi-
crobial prophylaxis, and new immunosuppressive 
drugs, UTI is considered as the most important 
cause of mortality in kidney recipients. In a study, 
the prevalence of bacterial agents in urinary tract 
infection in transplant recipients was reported 
97%, of which 90% were Gram-negative bacteria 
and 7% were Gram-positive and Escherichia coli 
was known as the most common cause of infec-
tion (71%) (12). In another study conducted by 
Vidal et al., E. coli (55.7%) was identified as the 
most common bacterial agent causing UTI in re-
cipients of kidney transplantation and other bac-
teria such as Pseudomonas aeruginosa (9.7%), K. 
pneumonia (9.7%), and Enterococcus (6.8%) were less 
commonly detected (13). The frequent and some-
times inappropriate use of antibiotics has led to 
the emergence of resistant bacteria. More than 70% 
of bacteria are resistant to at least one antibiotic. 
Incorrect times, inadequate dosage, or prolonged 
use of antibiotics are responsible for bacterial 
resistance and the use of adequate dosage and 
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adequate time in antibiotics application can pre-
vent antibiotic resistance.  
Methicillin-resistant S. aureus, and vancomycin-
resistant Enterococci (VRE) isolates is increasing in 
transplanted individuals and users of intravenous 
catheters. Therefore, study of prevalence of bac-
terial agents and their antibiotic resistance is nec-
essary (14). Also, the results of several studies 
showed that E. coli was the most common cause 
of urinary tract infections in recipients of the 
kidney (15, 16). The diseases caused by Uropath-
ogenic E. coli (UPEC) isolates certainly needs an-
tibacterial therapy; nevertheless, antibiotic-
resistant isolates of microorganisms cause more 
severe diseases for longer periods than their anti-
biotic-susceptible ones (17). UPEC strains are 
imposing economic costs for both community 
and hospital (18). In recent years, the spectrum of 
antibiotic resistance UTIs agents has changed 
(19). 
Considering the prevalence of bacterial agents in 
UTI in recipients of kidney and increasing antibi-
otic resistance, and because there is no detailed 
systematic review and meta-analysis of infections 
caused by these bacteria in kidney transplant re-
cipients, we aimed to evaluate the prevalence and 
antimicrobial resistance of bacterial uropathogens 
isolated from Iranian kidney transplant recipients.  
 
Materials and Methods 
 
Strategy search  
We searched according to Prisma proto-
col(PRISMA, http://www.prisma-statement.org) 
on the UTI infection, prevalence, occurrence and 
distribution of bacteria and pattern of antibiotic 
resistance among Iranian patients who received 
kidney transplant through online electronic data-
bases including Web of Sciences, PubMed, Sco-
pus and Cochrane Library), and Iranian databases 
such as  Iranmedex (www.iranmedex.com), Sci-
entific Information Database (www.sid.ir), Magi-
ran (www.Magiran.com), Irandoc 
(www.irandoc.ac.ir) with MeSh terms and text 
words such as hospital agents, bacterial infection, 
kidney transplant, post kidney transplant, antibi-
otic resistance pattern, and Iran. All Published 
studies in Persian and English languages between 
the 1990-2017 reporting the prevalence of bacte-
ria and pattern of antibiotic resistance among 
Iranian patients who received the kidney trans-
plant were studied. 
 
Inclusion anFd exclusion criteria 
The original cross-sectional or cohort references 
that presenting the prevalence/incidence and dis-
tribution of UTI, bacteria, and pattern of antibi-
otic resistance among Iranian patients who re-
ceived the kidney transplant were involved in this 
review. The kinds of literature with sample size 
of less than 50 deleted of the current study. We 
excluded review articles, low-quality articles, con-
gress and meeting abstracts, papers stated in lan-
guages other than English or Persian, abstract of 
papers, case report kinds of literature, unrelated 
papers. Also, this note should be added that to 
decrease the risk of bias, two researchers inde-
pendently searched. Articles introduced other 
than kidney transplants excluded from the pre-
sent study. Besides, other studies presenting viral, 
fungal and parasite infections in kidney trans-
plants excluded from our study. 
 
Data extraction 
A special data abstraction form was designed for 
investigators. The data such as; the first author’s 
name, time of the study, publication year, the lo-
cation of study, sample size, UTI prevalence, 
gender, and mean age were listed in these forms.   
 
Statistical analysis 
Data analysis was performed using Comprehen-
sive meta-analysis software (CMA). Prevalence 
was reported by 95% confidence intervals (CIs). 
To calculate the variance in each study for varia-
bles (antibiotic resistance, bacteria, UTI) the bi-
nomial distribution formula was used.  Owing to 
the large heterogeneity in the prevalence rates in 
the different studies, Cochrane Q and I2 Random 
Effects Model was used. The I2 test was used to 
evaluate the proportion of statistical heterogenei-
ty and the Q-statistic test was used to explain the 
degree of heterogeneity. A P-value of less than 
0.10 for the Q-test and I2 > 50% was considered 
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significant among the articles. For evaluating the 
possible bias of papers, Egger’s Linear Regres-
sion Test was used (20). 
 
Results  
 
Literature search and study descriptions  
The literature search process is described in Fig.1. 
Briefly, a total of 612 studies, only 11 met eligible 
inclusion criteria. The features of records en-
rolled in this review are abstracted in Table 1. 
The total sample size of the selected studies was 
3497 kidney transplant patients. The Prevalence 
of UTI among kidney transplant patients varied 
from 11.7% to 67.5%   (Table 1, Fig. 2). 
Studies were reported from North (Golestan 
province, N=1), South (Shiraz and Ahvaz prov-
inces, N=2), northeast (Mashhad, N=3) and 
most of those from Center (Tehran, N=5).  
 
 
 
Fig. 1: Flow chart of process was used for selecting the studies included in the current study 
 
 
Fig. 2: Forest plot of the meta-analysis on prevalence of UTI among Iranian patients who received kidney transplant 
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Table 1: Characteristics of enrolled studies for systematic and meta-analysis 
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Khosravi et al(41) 2009-2012 2014 Golestan  
and Ahvaz 
1165 32.6 34.8 65.2 39.6 ± 2 
 
Samanipour et 
al(14) 
2013-2014 2015 Tehran 116 60.3 30 70 41.3±13.3 
Shirazi et al(42) 1991-1996 2005 Tehran 87 33.3 34.4 65.6 - 
Pourmand et al(43) 2011-2012 2012 Tehran 173 27.2 39.3 61.7 40.8 ± 14 
Alimagham et al(44) 1993-1997 2002 Tehran 256 62.1 30 70 20-70 
Kian Ghanati et 
al(45) 
2009-2010 2012 Tehran 200 16.5 - - 10-70 
Shams et al(16) 2012-2014 2016 Mashhad 247 22.7 40.8 59.2 34.9 ±13.8 
Mansury et al(27) 2013-2015 2017 Mashhad 356 31.5 42.1 57.9 - 
Nazemian et al(46) 1998-2002 2007 Mashhad 83 67.5 24 76 50-66 
Fallahzadeh et 
al(47) 
1990-2008 2011 Shiraz 138 17.4 42.7 57.3 13.6 ± 3.5 
Pouladfar et al(40) 2012-2013 2015 Shiraz 676 11.7 50 50 5-87 
 
Also, 37% and 63% of patients respectively were 
female and male with a mean age of 5-87 years.  
Most of the patients with UTI had fever, dysuria, 
urinary frequency, abdominal pain, nocturia, 
change in the color and smell of urine. Also, in 
most cases, the UTI infection occurs after 3 
months of receiving the transplant. Asymptomat-
ic UTI was observed in one of the studies. Also, 
all studies included in this review were used of 
Kirby Bauer disk diffusion method for assess-
ment of antibiotic susceptibility. 
 
Overall effects 
Of total 11 papers were entered in the current 
study, based on the results of the heterogeneity 
test, studies had the heterogeneity (Q2 = 332.2, 
I2 = 96.9, P =0.003). For this reason, to combine 
the prevalence of UTI, the random effect model 
was used. The overall prevalence of UTI in recip-
ients of kidney among Iranian patients was 32.6% 
(23.1- 43.8%) (Table 2). 
The funnel plot was used for assessing publica-
tions bias (Fig. 3). In regards to the prevalence of 
UTI, and owing to the asymmetrical distribution 
of studies, probably bias was present in the cur-
rent study, but Egger weighted regression analysis 
did not confirm this matter (P = 0.94). 
 
 
Table 2: Subgroups meta‑analysis based on the most common bacteria involved in UTI patients 
 
Subgroups Number Random model Heterogeneity test Egger’s test 
 of study Bacteria prevalence 
(95% CI) (%) 
Z P P Q I2 t P 
Overall effects 11 32.6(23.1,43.8) 2.9 0.003 <0.001 332.2 96.9 0.07 0.94 
E. coli 10 41.3(34.2-48.7) 2.2 0.022 <0.001 56.8 93.3 1.4 0.19 
Enterococcus spp. 8 9.8(4.3-2.07) 5 0.000 0.00 93 91.3 4.8 0.000 
Klebsiella 7 11.9(6.8-20) 6.3 0.000 0.000 30.3 80.4 2.6 0.047 
Coagulase nega-
tive Staph 
6 9.4(4.8-17.4) 6.2 0.000 0.000 27.7 81.9 0.03 0.97 
Streptococcus 5 4.9(1.2-18.3) 3.9 0.000 0.000 52.2 92.3 1.5 0.22 
S. aureus 6 5.9(2.9-11.6) 7.3 0.000 0.003 17.8 72 1.1 0.32 
P. aeruginosa 7 10(7.2-13.8) 11.8 0.000 0.065 11.8 49.4 2.4 0.04 
Acinetobacter 4 1.8(0. 9-3.8) 10.4 0.000 0.06 7 57.7 1.9 0.18 
Other  10 11.4(5.3-22.7) 4.8 0.000 0.00 115 92.1 2.7 0.02 
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Fig. 3: Funnel plot for meta-analysis on prevalence of UTI among Iranian patients who received kidney transplant 
 
Table 3: Subgroups meta‑analysis of antibiotic resistance for gram negative recovered of UTI among Iranian pa-
tients received kidney transplant 
 
Subgroups Number 
of study 
Random model Heterogeneity test Egger’s test 
Resistance rate 
(95% CI) (%) 
Z P P Q I2 t P 
Amikacin 4 40.4(36.4, 44.5) 4.5 0.00 0.4 6.4 0.00 1 0.3 
Nitrofurantoin 5 40.9(27.8,55.5) 1.2 0.2 0.00 87.6 87.4 0.5 0.6 
Cotrimoxazole 9 70.6(57.3, 81.1) 2.9 0.003 0.00 28.6 72 1.1 0.28 
Cephalotin 6 60.8(50.7,70.1) 2.09 0.036 0.2 6.3 21.3 0.8 0.4 
Gentamicin 9 51.5(44,51.9) 0.39 0.69 0.27 9.9 19.2 0.1 0.8 
Ceftriaxon 3 68.1(44.3,85.2) 1.5 0.13 0.001 14.5 86.2 0.8 0.54 
Nalidixic acid 8 56.3(38.2,73) 0.6 0.49 0.00 29.2 76 0.4 0.6 
Cefixime 3 66(47.3, 80.8) 1.6 0.09 0.001 13.5 85.2 0.6 0.6 
Ciprofloxacin 8 54.5(32,75.3) 0.37 0.7 0.00 74 09 1.3 0.2 
Tetracycline 8 60.7(40.3,77.9) 1.02 0.3 0.00 39.4 82.2 1.8 0.1 
Pipracillin 3 45.2(14.9,79.6) 0.2 0.8 0.00 24.8 91.9 0.09 0.93 
Imipenem 3 14.3(5,34.7) 3 0.002 0.00 50.6 90.1 3.5 0.02 
Ceftazidime 3 89.5(44.4,98.9) 1.7 0.07 0.06 5.5 63.6 1 0.4 
Ampicillin‑Sulbactam 1 37.5(12.5,71.5) 0.6 0.4 1 0.00 0.00 - - 
Piperaciline-
tazobactame 
2 17.4(6.2, 40.4) 2.6 0.009 0.9 0.36 0.00 - - 
Chloramphenicol 6 42.7(31.4,54.7) 1.1 0.23 0.06 10.5 52.3 0.33 0.75 
Amoxicillin 4 69(32.9,91) 1 0.31 0.2 4.2 29.1 11.3 0.007 
Tobramycin 3 78.7(42.9, 94.8) 1.6 0.1 0.7 0.4 0.00 3 0.20 
Kanamycin 3 56.7(13.7,91.5) 0.24 0.80 0.1 3.4 42.7 0.2 0.8 
Ampicillin 2 91.2(81.1,96.2) 5.1 0.00 0.2 1.5 36.1 - - 
Ertapenem 2 17.2(9, 30.4) 4.1 0.00 0.1 1.8 47 - - 
Polymyxin B 2 26(5.1,69.8) 1 0.2 0.64 0.21 0.00 - - 
Erythromycin 3 86.3(52.8,97.2) 2 0.03 0.9 0.03 0.00 - - 
Kanamycin 3 62.7(12.9, 95.2) 0.4 0.6 0.1 4 50.5 0.46 0.72 
Polymyxin B 3 46(10.7,85.9) 0.1 0.8 0.2 3 33.4 0.23 0.85 
Aztreonam 2 53.5(30.6,75) 0.2 0.7 0.22 5.2 80.8 - - 
Cephalexin 3 86.3(52.8,97.2) 2 0.037 0.9 0.32 0.00 - - 
Carbenicillin 3 86.3(52.8,97.2) 2 0.037 0.9 0.32 0.00 - - 
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According to the subgroups analysis, among Gram-
negative causing UTI (Table 3), E. coli was the most 
dominant followed by Klebsiella with prevalence 
41.3%(34.2-48.7), and 11.9%(6.8-20), respectively. 
Also, amongst Gram-positive bacteria, the highest 
prevalence was related to Enterococcus spp. 9.8% (4.3-
2.07), and coagulase-negative staphylococci (CoNS) 
9.4% (4.8-17.4). Subgroups meta‑analysis of antibi-
otic resistance for Gram-negative recovered of UTI 
among Iranian patients who received kidney trans-
plant showed the most resistance to ampicillin 
91.2% (81.1, 96.2), followed by ceftazidime 89.5% 
(44.4, 98.9). Resistance to all three antibiotics )car-
benicillin, erythromycin and cephalexin) was 86.3% 
(52.8, 97.2). The minimum resistance was to 
imipenem with a prevalence of 14.3% (5, 34.7).  
As shown in Table 4, subgroups meta-analysis of 
antibiotic resistance for Gram-positive isolated of 
UTI among Iranian patients who received the 
kidney transplant, the most resistance was to 
cephalexin with prevalence 80.3% (50.4, 94.2), 
followed by amoxicillin with prevalence 74.3 %( 
48.1, 90). The lowest resistance was to polymyxin 
B with a prevalence of 11.6% (2.3, 41.7). 
Subgroups meta-analysis of antibiotic resistance 
for E. coli (Table 5) recovered of UTI among Ira-
nian patients who received kidney transplant re-
ported the most resistance to ampicillin 
91.2%(81.1,96.2), followed by ceftriaxone with a 
resistance rate of 87.9% (19.3, 99.5). The least re-
sistance was to imipenem 14.4% (4.2, 39.2), fol-
lowed by piperacillin-tazobactam 17.4% (6.2, 
40.4). 
 
Discussion 
 
In respect to developments in transplant, survival 
has resulted in extensive approval of kidney 
transplantation as the preferred treatment for the 
patients with End-Stage Renal Disease (ESRD) 
(21). But UTI is the highest frequent infection 
subsequently kidney transplantation (22, 23), with 
a range of 35 to 79% and responsible for around 
40–50% of all infectious problems following the 
kidney transplantation (24). Regarding the stud-
ies, most UTIs cases reported through kidney 
transplantation 1st-year post-transplantation (16). 
In the present study, the prevalence of UTI among 
kidney transplant patients varied from 11.7% - 
67.5%. This high variation in UTI prevalence likely 
referred to the varying in the incidences of re-
sistance, postoperative medical care, local out-
breaks, different immunosuppressive therapy, di-
verse diagnostic methods, hygienic statue, quality of 
nursing services in the general and transplantation 
surgery wards of hospitals, and administrating 
proper UTI prophylaxis (16, 24). 
 
Table 4: Subgroups meta‑analysis of antibiotic resistance for gram positive recovered of UTI among Iranian pa-
tients received kidney transplant 
Subgroups Number of 
study 
Random model Heterogeneity test Egger’s test 
Resistance rate 
(95% CI) (%) 
Z P P Q I2 t P 
Amikacin 4 69.4(45.9,85.8) 1.6 0.1 0.4 2.3 0.00 0.16 0.8 
Nitrofurantoin 4 35.8(11.3,70.9) 0.7 0.4 0.1 3.7 46 0.1 0.9 
Cotrimoxazole 4 45.9(26.1,67.1) 0.3 0.7 0.4 1.8 0.00 0.6 0.6 
Cephalotin 4 52.2(30.5,73.1) 0.1 0.8 0.3 2.1 6.2 2.1 0.27 
Gentamicin 5 64.4(36.6,85) 1 0.3 0.1 5 40.7 1.1 0.38 
Nalidixic Acid 4 45.3(26.1,66) 0.4 0.6 0.7 0.6 0.00 5.3 0.11 
Tetracycline 4 48.6(7.1,92.1) 0.04 0.9 0.03 6.8 70.7 0.3 0.7 
Amoxicillin 4 74.3(48.1,90) 1.8 0.06 0.32 2.2 12 1.8 0.3 
Tobramycin 3 60.2(34.1,81.6) 0.7 0.4 0.5 1 0.00 0.7 0.58 
Chloramphenicol 4 67(44.6,83.7) 1.4 0.1 0.5 1.2 0.00 0.2 0.8 
Kanamycin 3 71.5(41.6,89.8) 1.4 0.15 0.46 0.45 0.00 - - 
Polymyxin B 3 11.6(2.3,41.7) 2.3 0.019 0.9 0.005 0.00 - - 
Erythromycin 3 71.5(41.6,89.8) 1.4 0.15 0.4 0.5 0.00 - - 
Kanamycin 3 71.5(41.6,89.8) 1.4 0.15 0.4 0.5 0.00 - - 
Cephalexin 3 80.3(50.4,94.2) 1.9 0.04 0.6 0.1 0.00 - - 
Carbenicillin 3 75(32.8,94.9) 1.1 0.23 3.3 0.19 39.5 0.08 0.9 
Shapouri Moghaddam et al.: Prevalence and Antimicrobial Resistance of Bacterial Uropathogens … 
 
Available at:    http://ijph.tums.ac.ir                                                                                                      2172 
Table 5: Subgroups meta‑analysis of antibiotic resistance for E. coli isolated of UTI among Iranian patients received 
kidney transplant 
 
Subgroups Number 
of study 
Random model Heterogeneity test Egger’s test 
Resistance rate 
(95% CI) (%) 
Z P P Q I2 t P 
Amikacin 4 38.4(27.8.50.3) 1.9 0.056 0.19 4.7 36.4 0.62 0.59 
Nitrofurantoin 5 21(16.8,26) 9.3 0.00 0.42 3.8 0.00 1.1 0.3 
Cotrimoxazole 7 73(56.1,85.2) 2.6 0.009 0.001 22 77.2 0.9 0.4 
Cephalotin 3 63.6(56.6,70) 3.7 0.00 0.91 0.012 0.00 - - 
Gentamicin 5 53(47.1,58.9) 0.99 0.32 0.4 3.7 0.00 0.08 0.9 
Ceftriaxone 2 87.9(19.3,99.5) 1.1 0.25 0.00 11.6 91.4 - - 
Nalidixic acid 4 68.4(34.4,89.9) 1 0.28 0.00 25.5 88.2 1 0.4 
Cefixime 2 74.2(43,91.6) 1.5 0.12 0.00 9.9 89.9 - - 
Ciprofloxacin 5 61(23.6,88.8) 0.54 0.58 75.6 0.00 94.7 1.1 0.33 
Tetracycline 4 66(30,89.8) 0.86 0.38 0.00 35.5 91.5 1.5 0.27 
Pipracillin 2 66.7(24.2,92.6) 0.74 0.45 0.011 5.9 83.1 - - 
Imipenem 5 14.4(4.2,39.2) 2.6 0.009 38.1 0.00 89.5 3.1 0.05 
Ceftazidime 2 83.6(1.9,99.9) 0.57 0.56 0.001 12 91.7 - - 
Piperaciline-
tazobactame 
2 17.4(6.2,40.4) 2.6 0.009 0.33 0.9 0.00 - - 
Chloramphenicol 3 43.4(21.8,67.9) 0.51 0.60 0.1 4.3 54.2 0.039 0.97 
Ampicillin  2 91.2(81.1,96.2) 5.1 0.00 0.2 1.5 36.2 - - 
 
The overall prevalence of UTI among Iranian pa-
tients who receive kidney transplant was high up to 
32% (23.1- 43.8%). Similar to our findings, several 
kinds of literature from different regions of the 
world showed a high rate of UTI (22, 25, 26). 
Gram-negative bacteria are accountable for ap-
proximately 70% of UTI, particularly E. coli and 
Klebsiella pneumonia. As well as, several Gram-
positive such as Enterococcus spp. and Staphylococcus 
spp. are causing infection in patients who receiv-
ing kidney transplants (27). 
In this study, among Gram-negative pathogens 
causing UTI, E. coli was the most prevalent fol-
lowed by Klebsiella with prevalence 41.3%, and 
11.9%, respectively. 
Also, amongst Gram-positive bacteria, the high-
est prevalence was related to Enterococcus spp. 
9.8%, and coagulase-negative staphylococci 
(CoNS) 9.4%.  In agreement with our results, a 
cohort study conducted by Johannes Korth in-
vestigate the antibacterial susceptibility of Gram-
negative urinary pathogens after kidney trans-
plantation from 2009 to 2012 on 15.741 urine 
samples were acquired from 859 patients at the 
Transplant Outpatient Clinic of the University 
Hospital Essen, Germany. They reported that the 
most common discovered Gram-negative mi-
crobes were E. coli, followed by Klebsiella spp. and 
P. aeruginosa with prevalence 37%, 8%, and 4.5%, 
respectively (22). According to the previous stud-
ies, E. coli, Enterococcus, Staphylococcus, and Klebsiella 
were the most frequent (28, 29). Several studies 
in different years from various areas of the world 
are inconsistent with our findings. They showed 
the E. coli (among Gram-negative), and Enterococ-
cus (among Gram-positive) as the major microor-
ganisms recovered from UTI in kidney transplant 
patients (12, 30). 
Of course, contrary to our study, in some studies, 
other bacteria have been identified as the com-
mon cause of urinary tract infections.  For exam-
ple, Enterobacter cloacae, and Klebsiella spp. were re-
ported as the most causes of post-transplant 
UTIs, respectively (31).   
Prophylaxis with antibiotics is one of the im-
portant ways to prevent infections after the kid-
ney transplant. The presence of antibiotic-
resistant isolates can cause an increase in the 
mortality, longer hospital hospitalization, and im-
posing the higher hospital costs on the patients 
and healthcare systems than similar infections are 
caused by antibiotic-susceptible strains (32). 
The standard therapy to prevent UTI and other 
infections after the kidney transplant in most 
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health care settings is the use of Co-trimoxazole 
(TMP/SMX)(33). Also, the effectiveness of 
ciprofloxacin has confirmed (34). By contrast, in 
individuals who have an allergy to mentioned an-
tibiotics, nitrofurantoin is used as prophylaxis 
(35). Moreover, nitrofurantoin is an effective an-
tibiotic for UTI produced by ESBL producing E. 
coli (36). 
In the present study, the resistance rate of Gram-
negative bacteria, especially E. coli as the most 
common microorganism recovered from UTI to 
cotrimoxazole was more than 70%, and to 
ciprofloxacin was higher than 50%. This issue 
showing the existence of high resistance to these 
main antibiotics used in the treatment of UTI 
among Iranian who received kidney transplant, 
this possibly attributed to the overuse of these 
antibiotics which can result in restricted drug 
choice for the treatment of these infections (37). 
Also, the resistance rate to nitrofurantoin in 
Gram-negative organisms was 40.9%, Gram-
positive bacteria (35.8%), and E. coli (21%). Sub-
groups meta-analysis of antibiotic resistance for 
Gram-negative recovered of UTI among Iranian 
patients who received the kidney transplant 
showed the most resistance to ampicillin (91.2%) 
followed by ceftazidime (89.5%). 
Compatible with our findings, a study conducted 
by Korth reported that the resistance of Gram-
negative isolates to trimethoprim-
sulfamethoxazole, ciprofloxacin, and ceftazidime 
increased considerably (22). In a study from Méxi-
co, 22% and 33% of strains tested chiefly Gram-
negative isolates respectively, were resistant to 
ciprofloxacin and ampicillin (30). Of course, this 
resistance in comparison with our results obtained 
from the present study was relatively lower. 
As well as, another one from Turkey showed re-
sistance rates were 59.4%, 85.7%, 40.7%, and 
36.6%, of resistance to ciprofloxacin, cotrimoxa-
zole, ceftriaxone, and gentamicin, respectively 
(38), which it is in line with our study, too. 
According to the results, antibiotic resistance for 
E. coli isolated from UTI among Iranian patients 
who received kidney transplants reported the 
most resistance to ampicillin 91.2%, followed by 
ceftriaxone with a resistance rate of 87.9%. In 
contrast to the current findings, a study conduct-
ed by Kamath et al. in Poland, showed that about 
90% of Gram-negative strains were susceptible to 
ceftriaxone and ceftazidime (39). This high sensi-
tivity refers to the proper use of antibiotics used 
in this renal transplant center (30). 
The most susceptibility in Gram-negative bacteria 
was observed against Imipenem, and also, in 
Gram-positive microorganisms, the most effec-
tive antibiotic was Polymyxin B. This low re-
sistance probably came back to the low usage of 
those in kidney transplant settings of Iran. 
Undeniably, in this review, the resistance rates of 
the isolates were high to fluoroquinolones, third-
generation cephalosporins, and aminoglycosides. 
This high resistance results from antibiotic selec-
tion pressure and extensive use in kidney trans-
plant patients (40). Therefore none of the men-
tioned antibiotics except imipenem and piperacil-
lin-tazobactam would be suitable for antibiotic 
therapy of UTI in patients who received the kid-
ney transplant through hospitalization after kid-
ney transplant. 
UTI post-renal transplantation has a high influ-
ence on the transplant result. So, the best strate-
gies should be applied to decrease antibiotic re-
sistance and reinforce rational antibiotic treat-
ment. It should be pointed out that the periodic 
assessment of antibacterial profiles of bacteria 
related to UTI and reevaluation of the efficiency 
of antibiotic prophylaxis for the prevention of 
UTI in patients who receive the kidney transplant 
is required. An antimicrobial susceptibility should 
be considered instead of empiric therapy to pre-
vent antibiotic resistance and select the best anti-
biotic for treatment. 
 
Conclusion 
  
The combined prevalence of UTI was 32.6%. 
Gram-negative pathogens especially E. coli were 
the most agents of UTI in Iranian patients who 
received kidney transplant. Also, in Gram-
negative pathogens, the most resistance was to 
ampicillin that it needs a new strategy for prophy-
laxis and treatment of UTI after the kidney 
transplant.  
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